• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JULY 8, 2000

Sectoral Funds – Weekly roundup

This week witnessed the BSE Sensex posting 3.3% appreciation. The last few weeks have seen a revival in old economy stocks with the new economy taking a backseat for a change. However, this does not prevent IT funds from outperforming the others.

Open-ended, IT FundsNAV
(Rs)
Last
week
Last
month
Last
year
Since
inception
UTI Sector- Software25.604.30%12.30%0.00%96.20%
DSP ML Tech.com (Gr)10.094.20%7.20%0.00%18.10%
K P Internet Opport.(Gr)9.014.00%5.30%0.00%-5.90%
K P Infotech (Gr)32.333.60%9.10%218.20%180.30%
Magnum Sector Funds-IT17.713.00%9.20%0.00%148.20%
K Tech8.562.60%6.20%0.00%9.20%
IL&FS eCOM Fund (Gr)7.782.20%11.60%0.00%-42.90%
Birla IT Fund (Gr)22.852.20%4.80%102.00%18.20%
Chola Freedom Tech (Cum)17.751.40%9.40%28.30%25.40%
Pru ICICI Tech. (Gr)6.591.10%5.90%0.00%-33.00%
Alliance New Millenn (Gr)9.601.10%6.10%0.00%-37.20%
Tata IT Sector Fund13.790.90%6.70%119.60%29.90%
Sun F&C Emerg Tech (Gr)7.610.50%4.40%0.00%-11.10%

IT funds continued to see rapid growth. With the run-up in the prices of Infosys and Satyam (the cornerstone of most portfolios) IT funds continued to do well. All funds in this category witnessed growth over the week and the month. UTI’s Software fund was the star performer brushing aside misconceptions that private funds are better performers vis-ŕ-vis public sector funds.

Open-ended, Pharma FundsNAV
(Rs)
Last
week
Last
month
Last
year
Since
inception
Magnum Sector Funds-Pharma10.163.10%5.40%0.00%0.90%
K P Pharma (Gr)10.262.30%1.90%8.50%8.10%
UTI Sector-Pharma10.511.60%3.40%0.00%-11.90%

Pharma funds also witnessed NAV appreciation. Indian pharma stocks (Ranbaxy, Cipla, Dr Reddy) had some role to play in this. MNC pharma stocks remained steady. Buying by retail investors and institutions implies that there is appetite for pharma stocks. SBI’s Magnum Pharma was the outperformer over the week and the month.

Open-ended, FMCG FundsNAV
(Rs)
Last
week
Last
month
Last
year
Since
inception
Magnum Sector Funds-FMCG8.971.80%3.00%0.00%-13.10%
K P FMCG (Gr) 12.010.80%2.00%10.40%18.60%
Pru ICICI FMCG (Gr)10.030.60%3.50%-4.70%-2.30%

Performance of FMCG funds’ can at best be described as staid, compared to IT and pharma. However, all FMCG funds were in the positive over the week. The reasons are not hard to find – all FMCG funds have taken large exposures to Hindustan Lever which is on a roll. (Incidentally Hindustan Lever went ex-split this week and buying interest continued to remain high).

As in pharma, SBI’s Magnum FMCG was most impressive over the week and the month. However, it improved over a much lower base, when compared to Kothari FMCG and Pru-ICICI FMCG.

Public sector funds seem to be creeping into the limelight very slowly. This is evident from the fact that all the three sectoral star performers (UTI and SBI MF) were from the public sector.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407